New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription

Conventional chemotherapy remains the primary treatment option for triple-negative breast cancer (TNBC). However, the current chemotherapeutic drugs have limited effects on TNBC, and often lead to serious side effects as well as drug resistance. Thus, more effective therapeutic options are sorely ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Ming-Hao, Wu, Tian-Ying, Huang, Qiong, Jin, Guangyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Chemical Biology and Nucleic Acid Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6846596/
https://www.ncbi.nlm.nih.gov/pubmed/31584090
http://dx.doi.org/10.1093/nar/gkz835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6846596/
https://www.ncbi.nlm.nih.gov/pubmed/31584090
http://dx.doi.org/10.1093/nar/gkz835

Ejemplares similares